Physician profile
Dennis Morgan
NPI 1194723965
$11,471.18
in general payments reported to CMS, 2019-2025
77 companies · $2,393 in 2025
The $2,393 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,181 · 2020: $564 · 2021: $2,582 · 2022: $823 · 2023: $1,048 · 2024: $1,881 · 2025: $2,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,298 · Education: $23.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,297.98 |
| Education | $23.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene, LTD. | $1,350.00 | 2021 | |
| Merck Sharp & Dohme LLC | $718.41 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $638.23 | 2021-2025 | Trodelvy |
| Celgene Corporation | $542.11 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Pfizer INC. | $541.59 | 2019-2025 | |
| Incyte Corporation | $510.15 | 2019-2025 | Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $497.64 | 2019-2025 | |
| Amgen INC. | $465.28 | 2019-2023 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $445.02 | 2019-2025 | Opdivo |
| Genentech USA, INC. | $406.33 | 2019-2025 | Venclexta, Tecentriq |
| Genzyme Corporation | $365.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $358.37 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Seagen INC. | $329.94 | 2019-2023 | Adcetris, Tukysa |
| Janssen Biotech, INC. | $311.41 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Astellas Pharma US INC | $264.15 | 2019-2025 | Vyloy, Xospata |
Show all 75 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.